$TSHA
Taysha Gene Therapies, Inc.

2023 Q1 Form 10-K Financial Statement

#000095017023010343 Filed on March 28, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $4.700M $2.502M $2.500M
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.751M $7.341M $37.36M
YoY Change -23.7% -37.82% -9.59%
% of Gross Profit
Research & Development $12.51M $13.86M $91.17M
YoY Change 901.12% -63.44% 835.07%
% of Gross Profit
Depreciation & Amortization $300.0K $364.0K $1.200M
YoY Change 0.0% 74.16% 140.0%
% of Gross Profit
Operating Expenses $21.27M $21.20M $164.9M
YoY Change 1601.2% -57.36% -4.8%
Operating Profit -$16.56M -$162.4M
YoY Change -66.65% -6.24%
Interest Expense $1.374M -$597.0K $3.798M
YoY Change 61.84% -9.82% 165.97%
% of Operating Profit
Other Income/Expense, Net -$1.063M -$6.000K -$3.567M
YoY Change 26.1% 184.0%
Pretax Income -$17.62M -$55.72M -$166.0M
YoY Change -64.83% 10.59% -4.88%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$17.62M -$55.72M -$166.0M
YoY Change -64.83% 10.59% -4.88%
Net Earnings / Revenue -374.94% -2227.14% -6640.56%
Basic Earnings Per Share -$0.28 -$3.78
Diluted Earnings Per Share -$0.28 -$0.99 -$3.78
COMMON SHARES
Basic Shares Outstanding 63.47M 62.44M 43.95M
Diluted Shares Outstanding 63.26M 43.95M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $63.43M $87.88M $87.88M
YoY Change -34.36% -41.06% -41.06%
Cash & Equivalents $63.43M $87.90M $87.88M
Short-Term Investments
Other Short-Term Assets $532.0K $448.0K $8.537M
YoY Change -43.46% -48.09% -18.69%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $72.36M $96.42M $96.42M
YoY Change -32.31% -39.59% -39.59%
LONG-TERM ASSETS
Property, Plant & Equipment $14.64M $14.96M $25.91M
YoY Change -73.44% -70.43% -48.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.316M $1.316M $3.953M
YoY Change -66.81% 199.09% 5.58%
Total Long-Term Assets $29.24M $29.86M $29.86M
YoY Change -50.51% -45.07% -45.07%
TOTAL ASSETS
Total Short-Term Assets $72.36M $96.42M $96.42M
Total Long-Term Assets $29.24M $29.86M $29.86M
Total Assets $101.6M $126.3M $126.3M
YoY Change -38.79% -40.98% -40.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.002M $10.95M $10.95M
YoY Change -59.08% -49.7% -49.7%
Accrued Expenses $16.60M $18.29M $18.29M
YoY Change -37.63% -39.01% -39.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $328.0K
YoY Change
Total Short-Term Liabilities $54.46M $62.79M $62.79M
YoY Change 12.01% 21.34% 21.34%
LONG-TERM LIABILITIES
Long-Term Debt $38.16M $37.97M $37.97M
YoY Change 2.07% 2.08% 2.08%
Other Long-Term Liabilities $4.004M $4.130M $24.57M
YoY Change -86.31% 10.58% -17.09%
Total Long-Term Liabilities $42.17M $42.10M $62.54M
YoY Change -36.72% 2.86% -6.42%
TOTAL LIABILITIES
Total Short-Term Liabilities $54.46M $62.79M $62.79M
Total Long-Term Liabilities $42.17M $42.10M $62.54M
Total Liabilities $116.5M $125.3M $125.3M
YoY Change 1.13% 5.7% 5.7%
SHAREHOLDERS EQUITY
Retained Earnings -$419.1M -$401.4M
YoY Change 46.64% 70.34%
Common Stock $1.000K $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$14.95M $949.0K $949.0K
YoY Change
Total Liabilities & Shareholders Equity $101.6M $126.3M $126.3M
YoY Change -38.79% -40.98% -40.98%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$17.62M -$55.72M -$166.0M
YoY Change -64.83% 10.59% -4.88%
Depreciation, Depletion And Amortization $300.0K $364.0K $1.200M
YoY Change 0.0% 74.16% 140.0%
Cash From Operating Activities -$20.19M $14.28M -$88.39M
YoY Change -50.53% -135.46% -24.48%
INVESTING ACTIVITIES
Capital Expenditures $3.900M $2.309M $20.62M
YoY Change -53.72% -127.92% 34.73%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$61.00K $61.00K
YoY Change -100.0% -75.6% -100.98%
Cash From Investing Activities -$3.900M -$2.370M -$24.93M
YoY Change -65.87% -72.18% 15.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -370.0K 41.67M 52.10M
YoY Change 52.89% 357.63% 33.3%
NET CHANGE
Cash From Operating Activities -20.19M 14.28M -88.39M
Cash From Investing Activities -3.900M -2.370M -24.93M
Cash From Financing Activities -370.0K 41.67M 52.10M
Net Change In Cash -24.46M 53.57M -61.22M
YoY Change -53.4% -235.04% -38.48%
FREE CASH FLOW
Cash From Operating Activities -$20.19M $14.28M -$88.39M
Capital Expenditures $3.900M $2.309M $20.62M
Free Cash Flow -$24.09M $11.97M -$109.0M
YoY Change -51.08% -137.41% -17.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#Liabilities
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001806310
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-39536
CY2022 dei Entity Registrant Name
EntityRegistrantName
Taysha Gene Therapies, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3199512
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
3000 Pegasus Park Dr
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Ste 1430
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Dallas
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75247
CY2022 dei City Area Code
CityAreaCode
214
CY2022 dei Local Phone Number
LocalPhoneNumber
612-0000
CY2022 dei Security12b Title
Security12bTitle
Common stock, par value $0.00001 per share
CY2022 dei Trading Symbol
TradingSymbol
TSHA
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
91978421
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
63473349
CY2022 dei Auditor Name
AuditorName
Deloitte & Touche LLP
CY2022 dei Auditor Location
AuditorLocation
Dallas, Texas
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87880000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
149103000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8537000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10499000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
96417000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
159602000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
2637000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
2637000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14963000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50610000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10943000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1316000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1107000
CY2022Q4 us-gaap Assets
Assets
126276000
CY2021Q4 us-gaap Assets
Assets
213956000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10946000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
21763000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
18287000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
29983000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
33557000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
62790000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
51746000
CY2021Q4 tsha Build To Suit Lease Liability
BuildToSuitLeaseLiability
25900000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
37967000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
37192000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20440000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4130000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3735000
CY2022Q4 us-gaap Liabilities
Liabilities
125327000
CY2021Q4 us-gaap Liabilities
Liabilities
118573000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63207507
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63207507
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38473945
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38473945
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
402389000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
331032000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-401441000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-235649000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
949000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
95383000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
126276000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
213956000
CY2022 us-gaap Revenues
Revenues
2502000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
91169000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
131943000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
37360000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
41324000
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
36420000
CY2022 us-gaap Operating Expenses
OperatingExpenses
164949000
CY2021 us-gaap Operating Expenses
OperatingExpenses
173267000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-162447000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-173267000
CY2022 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
249000
CY2021 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
172000
CY2022 us-gaap Interest Expense
InterestExpense
3798000
CY2021 us-gaap Interest Expense
InterestExpense
1428000
CY2022 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
18000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3567000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1256000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-166014000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-174523000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.78
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.78
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.64
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.64
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43952015
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43952015
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37650566
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37650566
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
251302000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18604000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-174523000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
95383000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18275000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
253000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-166014000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
949000
CY2022 us-gaap Profit Loss
ProfitLoss
-166014000
CY2021 us-gaap Profit Loss
ProfitLoss
-174523000
CY2022 us-gaap Depreciation
Depreciation
1172000
CY2021 us-gaap Depreciation
Depreciation
492000
CY2022 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
1250000
CY2021 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
9750000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
18043000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
18184000
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
36420000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1315000
CY2022 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-906000
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-388000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2088000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3361000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-7804000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
14494000
CY2022 tsha Increase Decrease In Accrued Expense And Other Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherLiabilities
-9323000
CY2021 tsha Increase Decrease In Accrued Expense And Other Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherLiabilities
17542000
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
33557000
CY2021 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-8000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-88390000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-117042000
CY2022 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
4250000
CY2021 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
6250000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20619000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15304000
CY2022 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
61000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24930000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21554000
CY2021 tsha Proceeds From Term Loan Net
ProceedsFromTermLoanNet
39957000
CY2022 tsha Payment Of Shelf Registration Costs
PaymentOfShelfRegistrationCosts
358000
CY2021 tsha Payment Of Shelf Registration Costs
PaymentOfShelfRegistrationCosts
360000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
253000
CY2022 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-1042000
CY2021 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-514000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
52097000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
39083000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-61223000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-99513000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
151740000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
251253000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
90517000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
151740000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87880000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
149103000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
2637000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
2637000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
90517000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
151740000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
2775000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
641000
CY2022 tsha Property And Equipment In Accounts Payable And Accrued Expenses
PropertyAndEquipmentInAccountsPayableAndAccruedExpenses
4002000
CY2021 tsha Property And Equipment In Accounts Payable And Accrued Expenses
PropertyAndEquipmentInAccountsPayableAndAccruedExpenses
8282000
CY2021 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
606000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
23432000
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
387000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
141000
CY2021 tsha Research And Development License Not Yet Paid
ResearchAndDevelopmentLicenseNotYetPaid
3500000
CY2021 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
26250000
CY2022 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2020-02-13
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-401400000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87900000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates and assumptions in the Company’s financial statements relate to the determination of the fair value of the common stock prior to the IPO (as an input into stock-based compensation), estimating manufacturing accruals and accrued or prepaid research and development expenses, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">measurement of impairment of long-lived assets, and the allocation of consideration received in connection with the Astellas Transactions. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.1051
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. On March 10, 2023, the California Department of Financial Protection and Innovation closed the Silicon Valley Bank, Santa Clara, California (“SVB”), and appointed the FDIC as receiver. On March 12, 2023, the Treasury Department announced that depositors of SVB will have access to all of their money starting March 13, 2023. On March 14, 2023, the Company regained access to the full amount of its cash that</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">deposited with SVB. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management continues to believe to be of high credit quality. The Company has not experienced any losses on these deposits.</span></p>
CY2022 tsha Shelf Registration Term
ShelfRegistrationTerm
P3Y
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0772
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2819000
CY2022Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
454000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2918000
CY2022Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
454000
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
36400000
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3021000
CY2022 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
3100000
CY2021 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
4700000
CY2022Q4 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
0
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022Q4 tsha Derecognized Build To Suit Lease Asset Presented In Property Plant Equipment
DerecognizedBuildToSuitLeaseAssetPresentedInPropertyPlantEquipment
26300000
CY2022Q4 tsha Derecognized Build To Suit Lease Liability
DerecognizedBuildToSuitLeaseLiability
26500000
CY2022Q4 tsha Deferred Rent Liabiilities And Tenant Improvement Allowances
DeferredRentLiabiilitiesAndTenantImprovementAllowances
700000
CY2022Q4 us-gaap Cumulative Earnings Deficit
CumulativeEarningsDeficit
200000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16605000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
51109000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1642000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
499000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14963000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50610000
CY2022Q4 us-gaap Asset Impairment Charges
AssetImpairmentCharges
36400000
CY2022Q4 tsha Construction In Progress And Finance Lease Right Of Use Asset
ConstructionInProgressAndFinanceLeaseRightOfUseAsset
26300000
CY2022 us-gaap Depreciation
Depreciation
1200000
CY2021 us-gaap Depreciation
Depreciation
500000
CY2022Q4 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
8190000
CY2021Q4 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
11895000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2519000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7703000
CY2022Q4 tsha Accrued Property Plant And Equipment Current
AccruedPropertyPlantAndEquipmentCurrent
2081000
CY2021Q4 tsha Accrued Property Plant And Equipment Current
AccruedPropertyPlantAndEquipmentCurrent
2644000
CY2022Q4 tsha Accrued Clinical Trial Current
AccruedClinicalTrialCurrent
1473000
CY2021Q4 tsha Accrued Clinical Trial Current
AccruedClinicalTrialCurrent
1659000
CY2022Q4 tsha Accrued Severance
AccruedSeverance
1463000
CY2022Q4 tsha Lease Liability Current
LeaseLiabilityCurrent
1521000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
390000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1091000
CY2021Q4 tsha Accrued License Fees Current
AccruedLicenseFeesCurrent
3500000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
650000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1491000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
18287000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
29983000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
2486000
CY2022Q4 tsha Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
4840000
CY2021Q4 tsha Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
5218000
CY2022Q4 tsha Prepaid Clinical Trial
PrepaidClinicalTrial
2119000
CY2021Q4 tsha Prepaid Clinical Trial
PrepaidClinicalTrial
3298000
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
724000
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
545000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
388000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
148000
CY2022Q4 tsha Prepaid Bonus
PrepaidBonus
18000
CY2021Q4 tsha Prepaid Bonus
PrepaidBonus
427000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
448000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
863000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8537000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10499000
CY2021 tsha Built To Suit Lease Liability
BuiltToSuitLeaseLiability
26300000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
2873000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
452000
CY2022 us-gaap Lease Cost
LeaseCost
3325000
CY2022Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y10M17D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P11Y5M12D
CY2022Q4 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
454000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2485000
CY2022Q4 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
325000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2577000
CY2022Q4 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
73000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
19721000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
33541000
CY2022Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1760000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
11900000
CY2022Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
308000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
21641000
CY2022Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
1452000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1201000
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
320000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20440000
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1132000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
21641000
CY2022Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
1452000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
4848000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
4201000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
4301000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4372000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
3868000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
30563000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
52153000
CY2021Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0700
CY2022Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.1125
CY2021Q3 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2026-08-01
CY2021Q3 tsha Percentage Of Prepayment Of Facility
PercentageOfPrepaymentOfFacility
0.075
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
3000000.0
CY2021Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2021Q3 tsha Percentage Of Annual Default Interest Rate
PercentageOfAnnualDefaultInterestRate
0.05
CY2022 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
3700000
CY2018 tsha Net Operating Loss Carryforward Percentage
NetOperatingLossCarryforwardPercentage
0.80
CY2019 tsha Net Operating Loss Carryforward Percentage
NetOperatingLossCarryforwardPercentage
0.80
CY2020 tsha Net Operating Loss Carryforward Percentage
NetOperatingLossCarryforwardPercentage
0.80
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.15
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
6667000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
20000000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
13333000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
40000000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2033000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
37967000
CY2022Q4 tsha Probability Of An Option Exercise
ProbabilityOfAnOptionExercise
0.50
CY2022 us-gaap Revenues
Revenues
2500000
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
33600000
CY2022Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2941509
CY2021 tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Plan Adjustments And Amendments In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPlanAdjustmentsAndAmendmentsInPeriod
1434934
CY2021 tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod
3192600
CY2021 tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod
468258
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1652101
CY2022 tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Plan Adjustments And Amendments In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPlanAdjustmentsAndAmendmentsInPeriod
1923697
CY2022 tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod
4775676
CY2022 tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod
2267560
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1067682
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
0.85
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
0.15
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
1800
CY2022 tsha Excise Tax Rate Percentage
ExciseTaxRatePercentage
0.01
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18043000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18184000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-166014000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-174523000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43952015
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43952015
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37650566
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37650566
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.78
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.78
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.64
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.64
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7501416
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5878702
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0025
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0020
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.0491
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.0768
CY2022 tsha Effective Income Tax Rate Reconciliation Other Permanent Differences
EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
-0.0055
CY2021 tsha Effective Income Tax Rate Reconciliation Other Permanent Differences
EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
-0.0112
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2561
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2776
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
45609000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
37005000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
23216000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
14813000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
689000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1467000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
1000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
103000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
4607000
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
4169000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
3647000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
674000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
15563000
CY2022Q4 tsha Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
4574000
CY2022Q4 tsha Deferred Tax Assets Right Of Use Asset Impairment
DeferredTaxAssetsRightOfUseAssetImpairment
5525000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
103431000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
58231000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
2308000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
47000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
2355000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
101076000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
58231000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
42800000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
48400000
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
2900000
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
700000
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
400000
CY2022 dei Auditor Firm
AuditorFirmId
34

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
tsha-20221231_lab.xml Edgar Link unprocessable
0000950170-23-010343-index-headers.html Edgar Link pending
0000950170-23-010343-index.html Edgar Link pending
0000950170-23-010343.txt Edgar Link pending
0000950170-23-010343-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img37750962_0.jpg Edgar Link pending
img37750962_1.jpg Edgar Link pending
img37750962_10.jpg Edgar Link pending
img37750962_11.jpg Edgar Link pending
img37750962_12.jpg Edgar Link pending
img37750962_13.jpg Edgar Link pending
img37750962_14.jpg Edgar Link pending
img37750962_15.jpg Edgar Link pending
img37750962_16.jpg Edgar Link pending
img37750962_17.jpg Edgar Link pending
img37750962_18.jpg Edgar Link pending
img37750962_19.jpg Edgar Link pending
img37750962_2.jpg Edgar Link pending
img37750962_3.jpg Edgar Link pending
img37750962_4.jpg Edgar Link pending
img37750962_5.jpg Edgar Link pending
img37750962_6.jpg Edgar Link pending
img37750962_7.jpg Edgar Link pending
img37750962_8.jpg Edgar Link pending
img37750962_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tsha-20221231.htm Edgar Link pending
tsha-20221231.xsd Edgar Link pending
tsha-ex10_23.htm Edgar Link pending
tsha-ex10_24.htm Edgar Link pending
tsha-ex10_25.htm Edgar Link pending
tsha-ex23_1.htm Edgar Link pending
tsha-ex31_1.htm Edgar Link pending
tsha-ex31_2.htm Edgar Link pending
tsha-ex32_1.htm Edgar Link pending
tsha-ex32_2.htm Edgar Link pending
tsha-20221231_cal.xml Edgar Link unprocessable
tsha-20221231_def.xml Edgar Link unprocessable
tsha-20221231_htm.xml Edgar Link completed
tsha-20221231_pre.xml Edgar Link unprocessable